63 / 83
C
ervical
cancer
:
what
’
s
new
?
R
ev
A
ssoc
M
ed
B
ras
2015; 61(6):536-542
541
rence after less than two years of initial treatment, and
histological type of squamous cell carcinoma (SCC) are
associated with poor prognosis.
54,55
Regarding postoper-
ative prognostic factors, worst outcome is found in the
presence of positive meso-rectal lymph nodes, positive
lymphovascular invasion, and margins compromised by
tumor, with survival after two years around 10%.
54,55
R
esumo
Câncer de colo do útero: o que há de novo?
O câncer de colo uterino é o câncer ginecológico mais fre-
quente em nosso meio. Entre as mulheres, é o segundo
mais frequente, atrás apenas do câncer de mama. É a quar-
ta causa de morte por câncer no Brasil, com estimativa
de 15.590 casos novos (2014) e com 5.430 mortes (2013).
No intuito de atualizar informações para a melhora do
prognóstico, redução da morbidade e otimização do tra-
tamento dessa neoplasia, serão abordados neste artigo os
avanços nos conhecimentos sobre o câncer cervical. En-
tre os temas apresentados, estão o papel da cirurgia nos
diferentes estádios, o tratamento dos carcinomas local-
mente avançados, a preservação da fertilidade, o papel da
técnica do linfonodo sentinela, indicações e técnicas da
radio e quimioterapia, além de situações especiais.
Palavras-chave:
câncer, colo do útero, exenteração pél-
vica, preservação da fertilidade, biópsia de linfonodo sen-
tinela, braquiterapia, quimioterapia.
R
eferences
1.
INCA – Instituto Nacional de Câncer José Alencar Gomes da Silva. http://
www2.inca.gov.br/wps/wcm/connect/tiposdecancer/site/home/colo_utero/
definicao.
2.
Kato T, Takashima A, Kasamatsu T, Nakamura K, Mizusawa J, Nakanishi
T et al. Clinical tumor diameter and prognosis of patients with FIGO stage
IB1 cervical cancer (JCOG0806-A). Gynecol Oncol. 2015; 137(1):34-9.
3. Arimoto T, Kawana K, Adachi K, Ikeda Y, Nagasaka K, Tsuruga T et al.
Minimization of curative surgery for treatment of early cervical cancer: a
review. Jpn J Clin Oncol. 2015; 45(7):611-6.
4.
Kokka F, Bryant A, Brockbank E, Jeyarajah A. Surgical treatment of stage
IA2 cervical cancer. Cochrane Database Syst Rev. 2014; 5:CD010870.
5.
Halaska MJ, Robova H, Pluta M, Rob L. The role of trachelectomy in cervical
cancer. Ecancermedicalscience. 2015; 9:506.
6. Querleu D, Morrow CP. Classification of radical hysterectomy. Lancet Oncol.
2008; 9(3):297-303.
7.
Bansal N, Herzog TJ, Shaw RE, Burke WM, Deutsch I, Wright JD. Primary
therapy for early-stage cervical cancer: radical hysterectomy vs radiation.
Am J Obstet Gynecol. 2009; 201(5):485.e1-9.
8.
Shazly SA, Murad MH, Dowdy SC, Gostout BS, Famuyide AO. Robotic
radical hysterectomy in early stage cervical cancer: a systematic review and
meta-analysis. Gynecol Oncol. 2015; 138(2):457-71.
9.
Petsuksiri J, Chansilpa Y, Therasakvichya S, Suntornpong N, Thephamongkhol
K, Dankulchai P et al. Treatment options in bulky stage IB cervical carcinoma.
Int J Gynecol Cancer. 2008; 18(6):1153-62.
10. Yeo RM, Chia YN, Namuduri RP, Yap SP, Soong YL, Yam PK et al. Tailoring
adjuvant radiotherapy for stage IB-IIA node negative cervical carcinoma
after radical hysterectomy and pelvic lymph node dissection using the GOG
score. Gynecol Oncol. 2011; 123 (2):225-9.
11.
Minig L, Patrono MG, Romero N, Rodríguez Moreno JF, Garcia-Donas J.
Different strategies of treatment for uterine cervical carcinoma stage IB2-
IIB. World J Clin Oncol. 2014; 5(2):86-92.
12.
Rotman M, Sedlis A, Piedmonte MR, Bundy B, Lentz SS, Muderspach LI et
al. A phase III randomized trial of postoperative pelvic irradiation in Stage
IB cervical carcinoma with poor prognostic features: follow-up of a
gynecologic oncology group study. Int J Radiat Oncol Biol Phys. 2006;
65(1):169-76.
13.
Monk BJ, Wang J, Im S, Stock RJ, Peters WA, Liu PY et al. Rethinking the use
of radiation and chemotherapy after radical hysterectomy: a clinical-pathologic
analysis of a Gynecologic Oncology Group/Southwest Oncology Group/
Radiation Therapy Oncology Group trial. Gynecol Oncol. 2005; 96(3):721-8.
14. Chemoradiotherapy for Cervical Cancer Meta-analysis Collaboration.
Reducing uncertainties about the effects of chemoradiotherapy for cervical
cancer: a systematic review and meta-analysis of individual patient data
from 18 randomized trials. J Clin Oncol. 2008; 26(35):5802-12.
15.
Fujiwara K, Monk B, Devouassoux-Shisheboran M. Adenocarcinoma of the
uterine cervix: why is it different? Curr Oncol Rep. 2014; 16(12):416.
16.
Favero G, Pierobon J, Genta ML, Araújo MP, Miglino G, Del Carmen Pilar
Diz M et al. Laparoscopic extrafascial hysterectomy (completion surgery)
after primary chemoradiation in patients with locally advanced cervical
cancer: technical aspects and operative outcomes. Int J Gynecol Cancer.
2014; 24(3):608-14.
17. Chemoradiotherapy for Cervical Cancer Meta-analysis Collaboration
(CCCMAC). Reducing uncertainties about the effects of chemoradiotherapy
for cervical cancer: individual patient data meta-analysis. Cochrane Database
Syst Rev. 2010; (1):CD008285.
18.
Duenas-González A, Zarbá JJ, Patel F, Alcedo JC, Beslija S, Casanova L et al.
Phase III, open-label, randomized study comparing concurrent gemcitabine
plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin
versus concurrent cisplatin and radiation in patients with stage IIB to IVA
carcinoma of the cervix. J Clin Oncol. 2011; 29(13):1678-85.
19.
Duenas-González A, Orlando M, Zhou Y, Quinlivan M, Barraclough H.
Efficacy in high burden locally advanced cervical cancer with concurrent
gemcitabine and cisplatin chemoradiotherapy plus adjuvant gemcitabine
and cisplatin: prognostic and predictive factors and the impact of disease
stage on outcomes from a prospective randomized phase III trial. Gynecol
Oncol. 2012; 126(3):334-40.
20.
Dizon DS, Mackay HJ, Thomas GM, Werner TL, Kohn EC, Hess D et al.
State of the science in cervical cancer: where we are today and where we need
to go. Cancer. 2014; 120(15):2282-8.
21. Tangjitgamol S, Katanyoo K, Laopaiboon M, Lumbiganon P, Manusirivithaya
S, Supawattanabodee B. Adjuvant chemotherapy after concurrent
chemoradiation for locally advanced cervical cancer. Cochrane Database
Syst Rev. 2014; 12:CD010401.
22.
Petrelli F, De Stefani A, Raspagliesi F, Lorusso D, Barni S. Radiotherapy
with concurrent cisplatin-based doublet or weekly cisplatin for cervical
cancer: a systematic review and meta-analysis. Gynecol Oncol. 2014;
134(1):166-71.
23.
Ryu HS, Kang SB, Kim KT, Chang KH, Kim JW, Kim JH. Efficacy of different
types of treatment in FIGO stage IB2 cervical cancer in Korea: results of a
multicenter retrospective Korean study (KGOG-1005). Int J Gynecol Cancer.
2007; 17(1):132-6.
24.
Rydzewska L, Tierney J, Vale CL, Symonds PR. Neoadjuvant chemotherapy
plus surgery versus surgery for cervical cancer. Cochrane Database Syst Rev.
2010; (1):CD007406.
25.
Eddy GL, Bundy BN, Creasman WT, Spirtos NM, Mannel RS, Hannigan E
et al. Treatment of (‘bulky’) stage IB cervical cancer with or without
neoadjuvant vincristine and cisplatin prior to radical hysterectomy and
pelvic/para-aortic lymphadenectomy: a phase III trial of the gynecologic
oncology group. Gynecol Oncol. 2007; 106(2):362-9.
26.
Boutas I, Sofoudis C, Kalampokas E, Anastasopoulos C, Kalampokas T,
Salakos N. Fertility preservation in women with early stage cervical cancer.
Review of the literature. Eur J Gynaecol Oncol. 2014; 35(4):373-7.
27. Kyrgiou M, Mitra A, Arbyn M, Stasinou SM, Martin-Hirsch P, Bennett P et al.
Fertility and early pregnancy outcomes after treatment for cervical intraepithelial
neoplasia: systematic review and meta-analysis. BMJ. 2014; 349:g6192.